Charles K. Dargan - Mar 18, 2021 Form 4 Insider Report for BIOLARGO, INC. (BLGO)

Role
Chief Financial Officer
Signature
/s/ John R. Browning, Attorney-in-fact
Stock symbol
BLGO
Transactions as of
Mar 18, 2021
Transactions value $
$0
Form type
4
Date filed
5/24/2021, 08:19 PM
Next filing
Mar 28, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BLGO Option to purchase common stock Award $0 +300K +9.02% $0.00 3.63M Mar 18, 2021 Common stock 300K $0.17 Direct F1, F2, F3
transaction BLGO Option to purchase common stock Award $0 +2.5K +0.07% $0.00 3.63M May 21, 2021 Common stock 2.5K $0.18 Direct F4
transaction BLGO Option to purchase common stock Award $0 +30K +0.83% $0.00 3.66M May 21, 2021 Common stock 30K $0.18 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This amount reflects, in addition to the reported option grant, the expiration, during the first quarter of 2021, of options to purchase an an aggregate 130,000 shares of common stock.
F2 The Option is exercisable according to its vesting schedule: (i) 25,000 shares vested as of March 18, 2021, and then (ii) in equal monthly installments of 25,000 shares beginning April 18, 2021, so long as the Engagement Extension Agreement dated March 18, 2021, between Reporting Owner and Issuer, remains in force and effect.
F3 This Option was issued to the Reporting Person as compensation to serve as Issuer's Chief Financial Officer from January 31, 2021, through January 31, 2022.
F4 This Option was granted to Reporting Person to replace an option to purchase 10,000 shares that had been issued approximately 10 years ago to compensate Reporting Person for services to the Issuer and had recently expired unexercised due to a discrepancy between the original exercise price and current Issuer stock price, pursuant to plan adopted by the Issuer's Compensation Committee.
F5 This Option was granted to Reporting Person to replace an option to purchase 120,000 shares that had been issued approximately 10 years ago to compensate Reporting Person for services to the Issuer and had recently expired unexercised due to a discrepancy between the original exercise price and current Issuer stock price, pursuant to plan adopted by the Issuer's Compensation Committee.

Remarks:

The option issued to Reporting Person on March 18, 2021, reported herein on line one of Table II, was issued as compensation for service as Issuer's Chief Financial Officer, and was reported by Issuer on Form 8-K filed with the SEC on March 19, 2021.